Continuing anlotinib-based combination therapy following disease progression demonstrated meaningful disease stabilization in patients with advanced soft tissue sarcoma, according to a multicenter real-world study conducted across specialized Chinese medical centers. The retrospective investigation revealed that sustaining this multitargeted approach provided measurable disease control even after patients experienced prior progression on anlotinib.
Multitarget antiangiogenic tyrosine kinase inhibitors play a pivotal role in the clinical management of soft tissue sarcoma, but acquired therapeutic resistance remains a common hurdle during prolonged care. When progression arises, discontinuing antiangiogenic therapy can potentially trigger rapid tumor rebound, yet clinical evidence examining the continuation of targeted antiangiogenic interventions beyond progressive disease has remained notably limited.
To investigate the clinical outcomes of this management strategy, researchers initiated a retrospective review of medical records gathered from four representative Chinese sarcoma centers. The evaluation systematically gathered data on individuals with advanced soft tissue sarcoma who received sustained anlotinib-based combination regimens after developing documented progression on prior anlotinib therapy, establishing progression-free survival as the primary study endpoint.
The multicenter investigation ultimately included 217 qualifying patients treated between February 15, 2020, and March 31, 2023. At baseline, the participants had a median age of 61 years, with ages extending across a wide range from 26 to 88 years, and 131 individuals, representing 60.4 percent of the overall cohort, were male.
Following a median observation period of 7.4 months, researchers determined that the cohort achieved a median progression-free survival of 4.2 months, accompanied by a 95 percent confidence interval of 3.7 to 4.5 months. Furthermore, the analysis demonstrated that 21.9 percent of the evaluated patients maintained progression-free survival at six months.
Secondary efficacy evaluations revealed no objective responses across the cohort, but 158 patients successfully attained stable disease, culminating in an overall disease control rate of 72.8 percent. The median overall survival had not yet been reached at the conclusion of follow-up, while the 6-month overall survival rate stood at 91.4 percent.
Safety evaluations demonstrated that the prolonged combination treatment strategy exhibited an adverse event profile broadly consistent with earlier published reports regarding anlotinib, with no unexpected toxicities detected. The most frequent treatment-related adverse events documented during therapy were hypertension, occurring in 20.7 percent of participants, and hand-foot syndrome, recorded in 14.7 percent of treated individuals.
The study authors concluded that sustained anlotinib-based combination therapy beyond disease progression demonstrated promising clinical activity alongside an acceptable safety profile in advanced soft tissue sarcoma. Because these clinical findings derive from retrospective multicenter observations, the researchers noted that further validation in future clinical investigations will be necessary to confirm the outcomes.
Subject of Research: Sustained anlotinib combination therapy beyond progression in advanced soft tissue sarcoma
Article Title: Sustained Anlotinib-Based Combination Therapy Beyond Progression in Advanced Soft Tissue Sarcoma: A Large Multicenter Real-World Study
Article References: Yuan, Y., Ye, T., Fan, L., Sun, X., Wang, J., Luo, Z., & Chen, J. (2026). Sustained Anlotinib-Based Combination Therapy Beyond Progression in Advanced Soft Tissue Sarcoma: A Large Multicenter Real-World Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03856-1
Image Credits: AI Generated
DOI: 10.1007/s12325-026-03856-1
Keywords: anlotinib, soft tissue sarcoma, tyrosine kinase inhibitors, antiangiogenic therapy, disease progression, progression-free survival, overall survival, disease control rate, stable disease, hypertension, hand-foot syndrome, real-world study, retrospective study, multicenter study, tumor rebound, combination therapy
News Source: Ophelia Keating. (November 18, 2026). Sustained Anlotinib Regimens Stabilize Advanced Soft Tissue Sarcoma Beyond Initial Progression. Scienmag.



